Books on Actavis' jumbo nine-tranche bond partly backing the acquisition of Allergan were heard topping $65 billion and are due to close at 1:30 p.m. ET.» Read More
Salix, a maker of gastrointestinal drugs that has been courted by at least four potential suitors over the last year, has finally found a buyer.
The all-cash deal could be announced as soon as Sunday, according to these sources who requested not to be identified.
Allergan rose $2.88 or 1.2 percent, to $234.00. Baxter International Inc. rose$. 48 or. 7 percent, to $67.90. Boston Scientific Corp. rose$. 02 or. 1 percent, to $16.47.
Allergan rose $3.00 or 1.3 percent, to $234.12. Baxter International Inc. fell$. 75 or 1.1 percent, to $66.68. Boston Scientific Corp. fell$. 07 or. 4 percent, to $16.38.
NEW YORK, Feb 20- Valeant Pharmaceuticals International Inc is close to a deal to acquire bowel drug maker Salix Pharmaceuticals Ltd for around $160 per share, according to a person directly familiar with the matter. A deal of that size would be the largest ever for Valeant, which lost a takeover contest for Allergan Inc last year. The usually acquisitive Valeant...
Allergan rose$. 34 or. 1 percent, to $231.46. Baxter International Inc. fell $1.29 or 1.9 percent, to $66.13. Boston Scientific Corp. fell$. 13 or. 8 percent, to $16.32.
Allergan rose $1.62 or. 7 percent, to $231.12. Baxter International Inc. fell$. 98 or 1.4 percent, to $67.42. Boston Scientific Corp. fell$. 23 or 1.4 percent, to $16.45.
Allergan rose $1.10 or. 5 percent, to $230.60. Baxter International Inc. fell$. 91 or 1.3 percent, to $67.49. Boston Scientific Corp. fell$. 30 or 1.8 percent, to $16.38.
Allergan rose $1.13 or. 5 percent, to $230.63. Baxter International Inc. fell$. 87 or 1.3 percent, to $67.53. Johnson& Johnson fell$. 08 or. 1 percent, to $99.89.
CNBC.com found the best performing investors you probably have never heard of, but are beating the market these days. Here are their top picks.
NEW YORK, Feb 18- Actavis Plc, a generic drugmaker that has been steadily acquiring branded medicines, said it will change its name to Allergan Inc after it completes its planned $66 billion purchase of the Botox maker, signaling its growing focus on patent-protected drugs. Actavis, which began as a New Jersey- based generics company called Watson, took its current...
Feb 18- Actavis Plc posted a better-than-expected adjusted quarterly profit and raised its full-year earnings forecast, saying it expected strong sales of its new branded drugs. Actavis agreed to buy Allergan Inc last November for $66 billion, outbidding a hostile offer by activist investor William Ackman and Valeant Pharmaceuticals International Inc.
Actavis President & CEO Brent Saunders explains the new corporate name, and the strong earnings beat. "We keep surprising people," says Saunders.
Actavis, which bought Botox-maker Allergan Inc in November, makes drugs from research in its own pipeline, and copy cat versions of other popular drugs. Sales of the Actavis's branded drugs nearly tripled to $1.83 billion in North America in the fourth quarter, accounting for 45 percent of total revenue. For the fourth quarter ended Dec. 31, Actavis's net loss...
It was man versus machine when Bill Ackman interviewed Ray Dalio in New York.
Allergan chief David Pyott tells CNBC that dealing with "raiders" like Bill Ackman and Valeant Pharmaceuticals was a full-time job.
David Pyott, Allergan chairman & CEO, discusses the company's historic quarter, Bill Ackman's failed attempt to take over the company and the decision to subdivide the management team.
WASHINGTON, Feb 10- For the first time in 20 years, patients suffering from the eye disease glaucoma may soon have new treatments as several young companies look to shake up the $5.6 billion global market. No new class of medicine has been introduced since Pfizer Inc's N> Xalatan, known generically as latanoprost, in 1996.. The newcomers aim to disrupt...
M&A experts forecast there will be more major pharma deals in 2015 — but the U.K. won’t be a focus and the deals won’t be done for tax reasons.
Some of the names on the move ahead of the open.